Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel
NASDAQ:EQ

Equillium Q3 2025 Earnings Report

Equillium logo
$2.85 +0.05 (+1.75%)
As of 09:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Equillium EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Equillium Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Equillium Announcement Details

Quarter
Q3 2025
Date
11/13/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Equillium's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Equillium's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Equillium's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Equillium Earnings Headlines

Equillium (NASDAQ:EQ) Stock Rating Upgraded by Wall Street Zen
June 13 at 1:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30835852
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504
June 10, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/analysts-grow-more-confident-in-equilliums-eq-lead-asset-eq504-1779045/
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.tc pixel
June 16 at 1:00 AM  |  Porter & Company (Ad)
Equillium (NASDAQ:EQ) Insider Sells $632,000.00 in Stock
June 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30826894
Roth MKM Sticks to Its Buy Rating for Equillium (EQ)
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EQ/pressreleases/2279916/roth-mkm-sticks-to-its-buy-rating-for-equillium-eq/
Equillium (EQ) Receives a Buy from B. Riley Securities
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EQ/pressreleases/2282086/equillium-eq-receives-a-buy-from-b-riley-securities/
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ) (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies. The company has since advanced EQ001 through Phase 1 and Phase 2 clinical trials, evaluating its potential in steroid-refractory acute GVHD and exploring additional autoimmune indications, such as ulcerative colitis. Equillium’s R&D strategy emphasizes rigorous clinical development and targeted patient populations to address areas of high unmet medical need.

Equillium conducts its clinical trials and research activities primarily in the United States, collaborating with leading academic institutions and transplant centers. The company’s global development plan includes potential partnerships or licensing arrangements to expand access to its therapies beyond North America. Equillium maintains a focused corporate structure designed to streamline decision-making and support efficient execution of its clinical programs.

Under the leadership of President and Chief Executive Officer Roger Pomerantz, Equillium has built a management team with deep expertise in immunology, clinical development, and regulatory affairs. The company’s board and scientific advisory committee include seasoned industry professionals who guide Equillium’s strategic direction. As a clinical-stage enterprise, Equillium remains committed to advancing its immunotherapy candidates through pivotal trials and towards regulatory approval for patients in need.

View Equillium Profile
Earnings Tools